J2353 Octreotide injection, depot
Also known as: octreotide depot, Sandostatin LAR
Injection of octreotide, depot formulation. A long-acting somatostatin analog for neuroendocrine tumors.
In Plain Language
monthly hormone control injection; neuroendocrine tumor treatment
Clinical Context
Used for acromegaly, carcinoid syndrome, and other neuroendocrine conditions with monthly intramuscular administration.
RVU Information
CPT J2353 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J2353?
CPT J2353 (Octreotide injection, depot) is a J Codes (Drugs) code. Injection of octreotide, depot formulation. A long-acting somatostatin analog for neuroendocrine tumors.
How is J2353 administered?
CPT J2353 is administered by a healthcare provider, typically via injection or infusion. Used for acromegaly, carcinoid syndrome, and other neuroendocrine conditions with monthly intramuscular administration. It is used by Endocrinology, Oncology.
When is CPT J2353 used?
Used for acromegaly, carcinoid syndrome, and other neuroendocrine conditions with monthly intramuscular administration.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.